Immunotherapy and Targeted Therapy May Represent the Future of Later-line Lung Cancer Treatment
December 27th 2022Konstantinos Leventakos, MD, PhD, discusses the emergence of immunotherapy and lurbinectedin as beneficial treatments in small cell lung cancer, where osimertinib fits into the non–small cell lung cancer treatment paradigm, and more.
Expert and Patient Perspectives on Comprehensive Multiple Myeloma Treatment
December 22nd 2022Dr Kumar, Dr Patel, Falbo, and Ahlstrom highlight the importance of community-based discussions regarding adverse effects in multiple myeloma, the benefits of considering the whole treatment course, and subgroup analyses from the MAIA trial.
Thrombocytopenia Is Associated With High Levels of Fatigue in Myelofibrosis
December 20th 2022Jeanne M. Palmer, MD, discusses a retrospective analysis of the PERSIST-1 and PAC203 trials, the symptoms that were analyzed across patient populations, and what the findings from this research indicate about the relationship between low platelet counts and symptoms such as fatigue in myelofibrosis.
Lasofoxifene Improves Responses Vs Fulvestrant in ESR1-Mutated, ER+/HER2- Metastatic Breast Cancer
Single-agent lasofoxifene did not produce a statistically significant improvement in progression-free survival vs fulvestrant for patients with estrogen receptor–positive, HER2-negative metastatic breast cancer harboring ESR1 mutations.
Abemaciclib Plus Aromatase Inhibitor Generates Survival Benefit in HR+/HER2- Breast Cancer
The addition of abemaciclib to a nonsteroidal aromatase inhibitor elicited an improvement in overall survival vs a nonsteroidal aromatase inhibitor alone in patients with hormone receptor–positive, HER2-negative, early-stage breast cancer.
Multidisciplinary Management Stands at the Forefront of Breast Cancer Treatment
August 29th 2022Judy C. Boughey, MD, shares criteria for omission of sentinel lymph node surgery, the importance of not altering treatment based on identification of variants of uncertain significance, and the potential value of trastuzumab deruxtecan in HER2-low metastatic breast cancer.
Emerging Data are Expanding Treatment Options, Extending Survival Across Breast Cancer Subtypes
August 29th 2022Matthew P. Goetz, MD, discusses overall survival data with ribociclib and abemaciclib in estrogen receptor–positive, HER2-negative disease; the role of adjuvant pembrolizumab in patients with triple-negative breast cancer; and the efficacy of PARP inhibitors in earlier settings.
Tislelizumab Plus Chemotherapy Elicits Strong Survival Benefit in Esophageal Cancer
June 30th 2022The combination of tislelizumab and chemotherapy demonstrated a superior overall survival benefit compared with chemotherapy alone in patients with metastatic or unresectable esophageal squamous cell carcinoma
Iopofosine I-131 Under Further Investigation in CLOVER WaM Trial in Waldenström Macroglobulinemia
Sikander Ailawadhi, MD, discusses early efficacy observed with iopofosine I-131, the rationale of investigating the agent in the CLOVER WaM trial in patients with Waldenström macroglobulinemia, and how the radiotherapeutic could affect the treatment paradigm.
Key Subgroup Analyses Supports Tafasitamab Plus Lenalidomide for High-Risk R/R DLBCL
Treatment with tafasitamab plus lenalidomide demonstrated trends toward improved overall survival vs systemic regimens across key subgroups of patients with high-risk relapsed or refractory diffuse large B-cell lymphoma who are not eligible for transplant, according to findings from an observational, retrospective analysis of the cohort RE-MIND2 study.
Gastrointestinal Cancers Recap at ASCO 2022: Dr Tanios Bekaii-Saab
June 6th 2022OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.